CLAIMS

1. ~~Pidotimod~~ The use of pidotimod or a physiologically acceptable salt thereof, ~~for use~~ in the manufacture of a medicament for the treatment of inflammatory bowel disease.

2. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 1, characterized in that said inflammatory bowel disease is in form of Crohns' disease or ulcerative colitis.

3. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 1, characterized in that ~~it~~ the medicament is to be administered to a human.

4. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 1, characterized in that ~~it~~ the medicament is to be administered orally.

5. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 4, characterized in that ~~it~~ the medicament is to be administered by means of a solid or liquid formulation.

6. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said solid formulation is a tablet, a film-coated tablet, a capsule, a dragée or a sachet.

7. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said liquid formulation is a solution or a suspension.

8. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said solid formulation has a w/w concentration in pidotimod from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.

9. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said liquid formulation has a w/w concentration in pidotimod from 0.5% to 20%, more preferably from 1% to 10%, most preferably from 2% to 8%.

10. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 5, characterized in that said formulation has a content in pidotimod or a salt thereof, from 10 to 1000 mg per single dose, preferably from 50 to 800 mg per single dose.

11. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 1, characterized in that ~~it~~ the medicament is to be administered rectally.

12. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 11, characterized in that ~~it~~ the medicament is to be administered by means of a semi-solid or liquid formulation.

13. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 12, characterized in that semi-solid formulation is a suppository, a cream, a gel, an ointment or an emulsion.

14. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 12, characterized in that said liquid formulation is a solution or a suspension.

15. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 12, characterized in that said formulation has a w/w concentration in pidotimod or a salt thereof from 0.1% to 20%, preferably from 1% to 15%, more preferably from 5% to 10%.

16. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to any of the preceding claims, characterized in that ~~it~~ the medicament is to be

administered in combination or in temporal proximity with at least one additional active principle.

17. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 16, characterized in that said at least one additional active principle is selected from 5-ASA drugs, corticosteroids, immunosuppressive agents, and biologics.

18. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least one 5-ASA drug is selected from Sulfasalazine and Mesalazine.

19. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least one corticosteroid is selected from prednisone, budesonide or beclomethasone dipropionate.

20. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least immunosuppressive medication is azathioprine.

21. ~~Pidotimod or a physiologically acceptable salt thereof for~~The use according to claim 17, characterized in that said at least one biological agents is selected from infliximab and adalimumab.